In-Home Sensor Monitoring of Older Adults With Cancer
14. september 2020 oppdatert av: Washington University School of Medicine
In-Home Sensor Monitoring of Older Adults With Cancer: A Pilot Study
The investigators propose a pilot study of monitoring a sample of 6 older patients receiving active cancer treatment over a period of 6 months with in-home sensor monitors installed and maintained by Foresite Healthcare.
The investigators also propose exploring the beliefs and attitudes of those who are not willing to allow in-home sensor monitoring by asking them to complete a brief survey related to in-home sensor monitoring.
The investigators hypothesize that patients will find the equipment acceptable and unintrusive, that changes in home-monitored patient parameters will precede clinical events and that patient trajectories will be more fully characterized with the in home sensors.
Studieoversikt
Studietype
Intervensjonell
Fase
- Ikke aktuelt
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
65 år og eldre (Eldre voksen)
Tar imot friske frivillige
Nei
Kjønn som er kvalifisert for studier
Alle
Beskrivelse
Inclusion Criteria:
Arm A:
- Age ≥ 65
- Receiving systemic cancer therapy, including conventional chemotherapy, novel/targeted agents OR will begin systemic therapy within the next 4 weeks.
- Estimated life expectancy >1 year
- Anticipated to receive ongoing care at Siteman Cancer Center and its satellite sites
- Willing to have sensors installed in 1-2 primary living areas (e.g. living room and bedroom)
- Continuous home internet connection
- Able to understand and willing to sign an IRB-approved written informed consent document
Arm B:
- Age ≥ 65
- Receiving systemic cancer therapy, including conventional chemotherapy, novel/targeted agents OR will begin systemic therapy within the next 4 weeks.
- Estimated life expectancy >1 year
- Anticipated to receive ongoing care at Siteman Cancer Center and its satellite sites
- Able to understand and willing to sign an IRB-approved written informed consent document
Exclusion Criteria:
Arm A:
- Inability to read and understand English
- Only receiving hormonal agents (e.g. anti-estrogen or anti-androgen)
- Lives in institutional setting where instrumental activities of daily living are completed for patient by paid staff
Arm B:
- Inability to read and understand English
- Only receiving hormonal agents (e.g. anti-estrogen or anti-androgen)
- Lives in institutional setting where instrumental activities of daily living are completed for patient by paid staff
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Støttende omsorg
- Tildeling: Ikke-randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Arm A: In-Home Sensor Monitoring
Older adults with cancer undergoing systemic cancer treatment will undergo passive monitoring with motion sensors and bed sensor.
Passive infrared (PIR) motion sensors will be installed in their homes to detect presence in a particular room (e.g., bathroom or kitchen) as well as for specific activities.
There will also be a bed sensor, which is a pneumatic strip installed under the bed linens, which measures displacement of the resident's upper torso as he or she lies on the bed.
Participants will complete a baseline primarily self-administered survey, an abbreviated assessment with each follow up clinic visit (at least once per month) for 6 months of follow up and a final end of study assessment.
|
-Installed and maintained by Foresite Healthcare
|
|
Ingen inngripen: Arm B: Survey Only
Patients that choose to not proceed with in-home sensor monitoring will be asked to complete a brief survey that explores attitudes regarding in-home sensor monitoring
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Acceptability of in-home sensor monitoring as measured by a modified version of the Intelligent Systems for Assessment of Aging Technology Survey (Arm A only)
Tidsramme: 6 months
|
|
6 months
|
|
Heart rate (Arm A only)
Tidsramme: 6 months
|
-A meaningful change is heart rate outside the normal range of 60-100
|
6 months
|
|
Changes in gait speed of .1m/s or more (Arm A only)
Tidsramme: 6 months
|
6 months
|
|
|
Stride length (Arm A only)
Tidsramme: 6 months
|
6 months
|
|
|
Number of Falls (Arm A only)
Tidsramme: 6 months
|
6 months
|
|
|
Number of Hospitalizations (Arm A only)
Tidsramme: 6 months
|
6 months
|
|
|
Number of Emergency room visits (Arm A only)
Tidsramme: 6 months
|
6 months
|
|
|
Number of Infections requiring medical intervention (e.g. oral antibiotics) (Arm A only)
Tidsramme: 6 months
|
6 months
|
|
|
Number of grade ≥3 adverse events measured by CTCAE (Arm A only)
Tidsramme: 6 months
|
6 months
|
|
|
Patient reported outcomes of 10 common symptoms (Arm A)
Tidsramme: 6 months
|
|
6 months
|
|
Reason for not choosing in-home monitoring as measured by a modified version of the Intelligent Systems for Assessment of Aging Changes Technology Survey (Arm B only)
Tidsramme: At the time of invitation to participate in the study (Day 1)
|
|
At the time of invitation to participate in the study (Day 1)
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Tanya M Wildes, M.D., MSCI, Washington University School of Medicine
Publikasjoner og nyttige lenker
Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Forventet)
31. oktober 2020
Primær fullføring (Forventet)
30. april 2022
Studiet fullført (Forventet)
30. april 2022
Datoer for studieregistrering
Først innsendt
5. november 2019
Først innsendt som oppfylte QC-kriteriene
9. mars 2020
Først lagt ut (Faktiske)
13. mars 2020
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
16. september 2020
Siste oppdatering sendt inn som oppfylte QC-kriteriene
14. september 2020
Sist bekreftet
1. september 2020
Mer informasjon
Begreper knyttet til denne studien
Andre studie-ID-numre
- 202001189
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
NEI
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Nei
Studerer et amerikansk FDA-regulert enhetsprodukt
Nei
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .